Introduction
The renin-angiotensin system (RAS) is widely recognized as one of the most powerful signalling systems for controlling sodium balance, body fluid volume and arterial blood pressure. 1 The RAS consists of a number of biologically active angiotensin peptides, generated by an enzymatic cascade. 2 One of the effector peptides, angiotensin IV (Ang IV), has been shown to protect rats from limbic seizures in the focal pilocarpine model. 3 Moreover, both anticonvulsive and antiepileptogenic effects of Ang IV have been reported in the acute pentylenetetrazol (PTZ) and kindling model of generalized seizures in mice. [4] [5] [6] PTZ is a central nervous system convulsant that inhibits gammaaminobutyric acid-activated ion channels. 7 At low doses, PTZ induces absence seizures while moderate doses induce clonic seizures 8 and high dosage causes tonic-clonic seizures. These seizure episodes generally resolve in relatively short time. However, animals receiving continuously a high dose PTZ may suffer from generalized status epilepticus and eventually death. 9 In the mouse kindling model, subconvulsant doses of PTZ are repeatedly injected, leading to generalized clonic or tonic-clonic seizures. 10 PTZ kindling induces a compensatory increase in brain levels of the inhibitory neuromodulator adenosine and an upregulation of its A1 receptors, in order to diminish excitatory neurotransmission. [11] [12] [13] The anticonvulsive effects of Ang IV in the acute PTZ and kindling model in mice are suggested to be mediated by indirect interactions of Ang IV with adenosine A1 receptors. 5 Indeed, Ang IV pre-treatment caused a downregulation of A1 receptors, possibly by suppressing neuronal activity in brain areas involved in seizure development and thus preventing the adaptive adenosine-mediated response. 4 Another mechanism by which Ang IV could exert its anticonvulsive effects is by modulating dopamine (DA) receptors in the The peptide angiotensin IV (Ang IV) influences seizure susceptibility in rat and mouse models. Indeed, Ang IV has been shown to protect rats from limbic seizures in the focal pilocarpine model. Moreover, both anticonvulsive and antiepileptogenic effects of Ang IV have been reported in the acute pentylenetetrazol (PTZ) and kindling model of generalized seizures in mice. It has been hypothesized that the latter effects on seizures could be established via a modulatory effect on dopamine receptors in the basal ganglia or via an indirect interaction between Ang IV and adenosine A1 receptors. However, a possible role for insulin-regulated aminopeptidase (IRAP), the high affinity binding site for Ang IV, has not been studied yet. 
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Seizure j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / y s e i z basal ganglia. It has been shown that PTZ kindling led to increased brain DA levels 14, 15 and to a decrease in DA receptor density. 6 Ang IV treatment prevented the development of the PTZ kindling process and reversed the downregulation of DA receptors. 6 Furthermore, Ang IV administration in the striatum caused an increase in extracellular striatal DA levels 16 and intracerebroventricularly administered Ang IV protected the rats from pilocarpine induced limbic seizures. 3 The latter effect coincided with increased hippocampal extracellular levels of DA, 3 confirming that Ang IV affects the dopaminergic system. Since, to our knowledge, Ang IV does not directly interact with either adenosine or DA receptors, the observed anticonvulsive effects are most likely indirect effects. Ang IV has been shown to bind with low affinity to angiotensin AT1 receptors, 17, 18 however, the involvement of this receptor in seizure mechanisms remains controversial. 19, 20 In contrast, the role of the high affinity binding site of Ang IV, insulin-regulated aminopeptidase (IRAP), 21 in the anticonvulsive effects of Ang IV has not been studied before. IRAP is a membrane-associated zinc-dependent metallopeptidase of the M1 family with characteristic extracellular catalytic and transmembrane domains but a unique cytoplasmatic aminoterminal tail. 22, 23 Ang IV is a potent and competitive IRAP inhibitor, binding to the catalytic site of this enzyme 24 and has been shown to decrease seizure severity in PTZ models, as described above. Taken together, these data suggest a possible IRAP mediated anticonvulsive effect. Therefore, in the present study, we compared the susceptibility to PTZ-induced generalized seizures in mice in which the IRAP gene was deleted, comparing their responses to the wild-type littermate controls.
Materials and methods

Animals
Male insulin-regulated aminopeptidase wild-type (IRAP +/+ ) and knock-out (IRAP À/À ) mice of three to six months old were used. IRAP mice were generated by Ozgene (Ozgene Ptd Ltd., Bentley DC, Australia) as described before 21 and bred at the animal house of the Vrije Universiteit Brussel. Mice used in the experiments were offspring from heterozygous IRAP breeding pairs on a C57Bl/6 background. The mice were housed under a constant light and dark cycle (lights on at 0700 h and off at 2100 h) and were given free access to food and water. 
Video electrocorticography (ECoG) telemetry monitoring
IRAP
+/+ and IRAP À/À mice (n = 3 for each group) were anesthetized by an intraperitoneal (i.p.) injection of xylazine (Bayer, SintTruiden, Belgium)/ketamine (Ceva, Brussel, Belgium) (10/100 mg/ kg). Through an incision in the abdomen and the scalp, a transmitter (model TA10EA-F20, Data Science International, St Paul) was placed in the abdomen and electrical leads of the transmitter were tunnelled to the skull. Animals were placed on a stereotaxic frame in order to fix screws, connected to the leads, in the skull at following coordinates: lateral, À2.0/+2.0; anterior posterior, À2.1. The electrodes and screws were covered with dental acrylic cement (Dentsply Caulk, Milford, USA). After the surgery, mice were given ketoprofen (4 mg/kg, i.p.; Merial, Essex, United Kingdom) and were allowed to recover for 7 days in the animal house. During this period, amoxicillin (1 mg/kg; Fort Dodge Animal Health Benelux, Naarden, Netherlands) was administered i.p. twice daily. The basal ECoG of the animals was measured overnight for at least 12 h. One week after surgery, these mice were subjected to PTZ-induced seizures as described below in Section 2.3. The obtained ECoG spectra were analyzed using Notocord-hem Evolution 1 software (Notocord, Croissy, France). 
Seizure severity assessment in IRAP mice
The experiments for the assessment of PTZ seizure thresholds were conducted with separate groups of unanesthesized mice (n = 8 or n = 16 for each group). Mice were restrained and a 29 G needle, attached to a polyethylene tubing (Smiths, Keene, USA), was inserted into the lateral tail vein. The needle was secured to the tail with tape and the tubing was connected to a 2.5 ml Hamilton syringe mounted to a CMA infusion pump (Microdialysis, Solna, Sweden). While PTZ (Sigma, St-Louis, MO, USA) solution (7.5 mg/ml) was infused at a constant rate of 150 ml/min, the animal was able to move freely in a cage made of Plexiglas.
The behavioural endpoints were (i) myoclonic twitch, (ii) generalized clonic phase with loss of righting reflexes and (iii) tonic hindlimb extension. The time from the start of the infusion to the onset of each behaviour was recorded. The threshold doses were calculated with the following formula: PTZ threshold dose (mg/ kg) = (PTZ concentration (mg/ml) Â infusion rate (ml/s) Â infusion duration (s) Â 1000)/weight of mouse (g). 25 
Data analysis
Data were analyzed by using the non-parametric two-tailed Mann-Whitney's test (a = 0.05).
Results
The occurrence of seizure events in IRAP +/+ and IRAP À/À mice was assessed by an investigator blinded to the genotype. This visual scoring system was validated by using video electrocorticography (ECoG) telemetry monitoring. The representative basal ECoG pattern of an IRAP À/À mouse (Fig. 1A lower panel) did not show any abnormalities in comparison to the IRAP +/+ mouse ( Fig. 1A upper panel) . The intravenous infusion of PTZ at a constant flow rate of 150 ml/min elicited a stereotyped seizure response.
The ECoG showed an array of epileptiform activities that started with a myoclonic twitch (Fig. 1B , indicated with arrow), followed by clonic seizures (Fig. 1C) with loss of righting reflexes (Fig. 1C , indicated with arrow) and tonic seizures (Fig. 1D , indicated with arrow). The behaviours progressed rapidly from one stage to the other as the infusion progressed. Thus the observed seizure events coincided with ECoG abnormalities.
To investigate the involvement of IRAP in seizure generation, PTZ dose thresholds were determined for each behaviour associated with the epileptiform activities described above, in IRAP +/+ and IRAP À/À mice. Only body weight and duration of infusion were required for the calculations, since PTZ dose and infusion rates are constant for all animals (see Section 2.3).
Compared to IRAP +/+ mice, IRAP À/À mice showed significantly increased PTZ thresholds for myoclonic twitch ( Fig. 2A) and generalized clonic seizures with loss of righting reflexes (Fig. 2B) but not for tonic hindlimb extension (Fig. 2C) .
Discussion
The results of this study show that the deletion of IRAP in mice is accompanied with a lower susceptibility to PTZ-induced seizures. The underlying molecular mechanism of this anticonvulsive effect against generalized seizures is not yet elucidated. However, we can speculate based on what is known about IRAP. IRAP is co-localised with the glucose transporter GLUT4 in vesicles where the amino terminus projects in the cytoplasm and the catalytic domain is present in the lumen. 22 It has been hypothesized that the binding of ligands to IRAP increases the translocation and positioning of GLUT4 at the membrane, resulting in an increased glucose uptake 26 which could offer protection against seizures.
However, it has been described that IRAP À/À mice show normal glucose uptake 27 and maintain normal glucose homeostasis, 28 indicating that this mechanism is unlikely to explain the lower susceptibility of these mice to generalized seizures. IRAP has been identified as the high affinity binding site for Ang IV 21 and could be involved in mediating anticonvulsive effects via two remaining possible mechanisms. First, IRAP may act as a receptor which, upon binding of the ligand to its C-terminal domain, interacts with cytoplasmatic proteins. Ang IV and other IRAP ligands would act as agonists to induce IRAP dimerisation and elicit intracellular signalling 22, [29] [30] [31] that could result in anticonvulsive effects. Second, the catalytic activity of IRAP can be inhibited by its ligands, leading to an increased half-life of neuropeptide substrates, which potentiate biological effects. 32 This hypothesis is supported by in vitro studies in which IRAP is known to cleave a number of small neuropeptides, such as substance P, met-enkephalin and somatostatin-14. 33 In line with this hypothesis, it is possible that the levels of some of these circulating neuropeptides could be higher in IRAP À/À mice in comparison with IRAP +/+ mice and could explain the anticonvulsive effects that accompany IRAP deletion.
In conclusion, our data attribute an important role to IRAP in the generation of generalized seizures, suggesting that IRAP is a potential therapeutic target in epilepsy research. However, the exact mechanism by which IRAP deletion leads to anticonvulsive effects remains speculative and requires further work.
